Novel risk factors for cardiovascular disease in rheumatoid arthritis

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 267-286

  Amaya Amaya, Jenny ^a   Sarmiento Monroy, Juan Camilo ^a   Mantilla, Ruben Dario ^a   Pineda Tamayo, Ricardo ^a,b   Rojas Villarraga, Adriana ^a   Anaya, Juan Manuel ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b ART Medica IPS   (Colombia)

Author keywords

Cardiovascular disease; Familial autoimmunity; Non traditional risk factors; Rheumatoid arthritis

Indexed keywords

ABDOMINAL OBESITY; ADULT; ARTICLE; AUTOIMMUNITY; BODY MASS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; COLOMBIA; CROSS-SECTIONAL STUDY; DATA EXTRACTION; DISEASE DURATION; FEMALE; HEALTH PRACTITIONER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS;

ADULT; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; COLOMBIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84879549613     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8398-7     Document Type: Article

References (187)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094-108.
2. Rojas-Villarraga A, Ortega-Hernandez O, Gomez L, Pardo A, López-Guzmán S, Arango-Ferreira C, et al. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin Arthritis Rheum. 2008;38:71-82.
3. Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Díaz C, Anaya JM, Rojas-Villarraga A. Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis. 2012;2012:371909.
4. Cárdenas-Roldán J, Amaya-Amaya J, Castellanos-de la Hoz J, Giraldo-Villamil J, Montoya-Ortiz G, Cruz-Tapias P et al., Autoimmune thyroid disease in rheumatoid arthritis: a global perspective. Arthritis.;2012 (in press).
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
6. Colombia, Law No 30. Public service in higher education, 28 Dec 1992.
7. Colombia, Law No 115. General on education, 8 Feb 1994.
8. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya J-M. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012;2012:254319.
9. Gershwin ME, Shoenfeld Y, Cervera R. Diagnostic criteria in autoimmune diseases. 1st ed. New York: Humana Press; 2008.
10. Anaya J-M, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol. 2007;3:623-35. (Pubitemid 47096486)
11. Anaya J-M. The autoimmune tautology. Arthr Res Ther. 2010;12:147.
12. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999;26:743-5. (Pubitemid 29125603)
13. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association, Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000;320:705-8.
14. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261-77. (Pubitemid 39546229)
15. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005;96:53E-9E. (Pubitemid 41140371)
16. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
17. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American heart association and the American college of cardiology. Circulation. 1999;100:1481-92. (Pubitemid 29451714)
18. Disease C. The impact of cardiovascular risk factors on the age-related excess risk of coronary heart disease. Int J Epidemiol. 2006;35:1025-33.
19. Jones DW, Hall JE. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension. 2004;43:1-3. (Pubitemid 38031902)
20. Statements P. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-63.
21. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32:1769-818.
22. Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, et al. Family history of premature coronary heart disease and coronary artery calcification: multi-ethnic study of atherosclerosis (MESA). Circulation. 2007;116:619-26. (Pubitemid 47356346)
23. B.C. Society, B.H. Association, B.H. Society, D.W. Convenor, A. Rees, Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 1998;80(Suppl 2):S1-29.
24. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27:978-83. (Pubitemid 38420225)
25. Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: association for weight management and obesity prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr. 2007;85:1197-202. (Pubitemid 46740459)
26. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res. 2007;4:32-8. (Pubitemid 46649071)
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.
28. OCBEM Levels of Evidence Working Group, The Oxford 2011 levels of evidence;2011.
29. Ziprkowski L, Schewach-Millet M, Sandbank M, Mozes M. Arterial thrombosis during corticosteroid therapy. Harefuah. 1971;80:540-3.
30. Anonymous. Unraveling the link between rheumatoid arthritis and heart disease. Inflammation appears to be the common denominator. Screening, medical interventions are key to reducing risk. Duke Med Health News. 2008;14:8.
31. Abdel-Khalek MA, El-Barbary AM, Essa SA-M, Ghobashi AS. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2153-9.
32. Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Rheumatoid arthritis, periodontal disease and coronary artery disease. Clin Rheumatol. 2008;27:421-7.
33. Ahmed HMMS, Youssef M, Mosaad YM. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol. 2010;29:1237-43.
34. Ajeganova S, Ehrnfelt C, Alizadeh R, Rohani M, Jogestrand T, Hafström I, et al. Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset - a prospective cohort study. Rheumatology. 2011;50:1785-93.
35. Arlestig L, Wållberg Jonsson S, Stegmayr B, Rantapää- Dahlqvist S. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:866-71. (Pubitemid 351166438)
36. Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis. 2007;195:e135-41.
37. Banerjee S, Compton AP, Hooker RS, Cipher DJ, Reimold A, Brilakis ES, et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol. 2008;101:1201-5.
38. Bartoloni Bocci E, Marchesi S, Delle Monache F, Vaudo G, Giordano A, Ragni Alunni F, et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Reumatismo. 2011;57(1):16-21.
39. Bazzichi L, Ghiadoni L, Rossi A, Bernardini M, Lanza M, De Feo F, et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol Med. 2009;15:402-6.
40. Book C, Saxne T, Jacobsson LTH. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol. 2005;32:430-4. (Pubitemid 40381412)
41. Chen Y, Dawes PT, Packham JC, Mattey DL. Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J Rheumatol. 2011;38:802-9.
42. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52:3045-53. (Pubitemid 41447084)
43. Cvetkovic JT, Wallberg-jonsson S, Stegmayr B, Lefvert AK, Wållberg-jonsson S, Rantapää-dahlqvist S, et al. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-α, IL-1ß, and IL-1Ra genes. J Rheumatol. 2002;29(2):212-9. (Pubitemid 34118764)
44. Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, et al. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum. 2011;63:1497-506.
45. Davis JM, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56:820-30. (Pubitemid 46399429)
46. da Cunha VR, Brenol CV, Brenol JCT, Fuchs SC, Arlindo EM, Melo IMF, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012;41:186-91.
47. Del Rincón I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 2003;48:1833-40. (Pubitemid 36828677)
48. del Rincón I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 2004;50:3813-22. (Pubitemid 39643928)
49. Del Rincón I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis. 2007;195:354-60. (Pubitemid 350087940)
50. del Rincón I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005;52:3413-23. (Pubitemid 41612207)
51. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R634-43.
52. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol. 2004;31:867-74. (Pubitemid 38585808)
53. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32:435-42. (Pubitemid 40381413)
54. Daza L, Aguirre M, Jimenez M, Herrera R, Bollain JJ. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol. 2007;26:533-7. (Pubitemid 46359293)
55. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol. 2007;34:681-8. (Pubitemid 46641371)
56. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol. 2007;34:943-51. (Pubitemid 46774836)
57. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5.
58. Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR. Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovasc Disord. 2007;7:31.
59. El-Barbary AM, Kassem EM, El-Sergany MAS, Essa SA-M, Eltomey MA. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol. 2011;38:828-34.
60. Elkan A-C, Håkansson N, Frostegård J, Cederholm T, Hafström I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2009;11:R37.
61. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 2008;58:359-69. (Pubitemid 351294870)
62. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198-200. (Pubitemid 38058729)
63. Foster W, Carruthers D, Lip GYH, Blann AD. Relationships between endothelial, inflammatory and angiogenesis markers in rheumatoid arthritis: implications for cardiovascular pathophysiology. Thromb Res. 2009;123:659-64.
64. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-14.
65. Galiutina OIu BO. Relationship of silent myocardial ischemia with the course of rheumatoid arthritis and hyperhomocysteinemia. Lik Sprava. 2011;1-2:48-52.
66. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJF. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology. 2008;47:1780-4.
67. Giles JT, Szklo M, Post W, Petri M, Blumenthal RS, Lam G, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the multi-ethnic study of atherosclerosis. Arthritis Res Ther. 2009;11:R36.
68. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:125-32.
69. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1219-23. (Pubitemid 40995373)
70. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine. 2003;82:407-13. (Pubitemid 37445043)
71. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114:647-52. (Pubitemid 36703233)
72. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PloS One. 2009;4:e6242.
73. Grover S, Sinha RP, Singh U, Tewari S, Aggarwal A, Misra R. Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol. 2006;33:244-7. (Pubitemid 43209298)
74. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther. 2007;9:R116.
75. Hjeltnes G, Hollan I, Førre Ø, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40:422-7.
76. Innala L, Möller B, Ljung L, Magnusson S, Smedby T, Södergren A, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther. 2011;13:R131.
77. Kao AH, Krishnaswami S, Cunningham A, Edmundowicz D, Morel PA, Kuller LH, et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol. 2008;35:61-9.
78. Kao AH, Wasko MCM, Krishnaswami S, Wagner J, Edmundowicz D, Shaw P, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol. 2008;102:755-60.
79. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled study. Ann Rheum Dis. 2007;66:28-33. (Pubitemid 46044857)
80. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1489-97. (Pubitemid 34620194)
81. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res. 2007;4:130-5. (Pubitemid 47167497)
82. Lau CS, McLaren M, Hanslip J, Kerr M, Belch JJ. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis. 1993;52:643-9. (Pubitemid 23280432)
83. Lertnawapan R, Bian A, Rho YH, Kawai VK, Raggi P, Oeser A, et al. Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2011;38:2297-300.
84. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1665-70.
85. López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419-24.
86. López-Mejías R, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Filloy JA, Gómez-Vaquero C, et al., NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis. (2012).
87. Mabrouk MM, Ghazy MA, Hassen HT. Serum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Egypt J Immunol. 2010;17:87-99.
88. Mac Mullan PA, Peace AJ, Madigan AM, Tedesco AF, Kenny D, McCarthy GM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology. 2010;49:240-5.
89. Mahajan V, Handa R, Kumar U, Sharma S, Gulati G, Pandey RM, et al. Assessment of atherosclerosis by carotid intimomedial thickness in patients with rheumatoid arthritis. JAPI. 2008;56:587-90.
90. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-32. (Pubitemid 40365093)
91. Marasovic-Krstulovic D, Martinovic-Kaliterna D, Fabijanic D, Morovic-Vergles J. Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? Rheumatology. 2011;50:1505-12.
92. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1550-5.
93. Mattey DL, Dawes PT, Nixon NB, Goh L, Banks MJ, Kitas GD. Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. Ann Rheum Dis. 2004;63:420-5. (Pubitemid 38453309)
94. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3940-8. (Pubitemid 350262319)
95. Mattey DL, Thomson W, Ollier WER, Batley M, Davies PG, Gough AK, et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum. 2007;56:1408-16. (Pubitemid 46764067)
96. Mazzantini M, Talarico R, Doveri M, Consensi A, Cazzato M, Bazzichi L, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol. 2010;37:2232-6.
97. McCoy SS, Crowson CS, Gabriel SE, Matteson EL. Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol. 2012;39:954-8.
98. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 2001;40:640-4.
99. McLaren M, Alkaabi J, Connacher M, Belch JJF, Valenete E. Activated factor XII in rheumatoid arthritis. Rheumatol Int. 2002;22:182-4. (Pubitemid 35025077)
100. Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis. 2002;61:994-9. (Pubitemid 35221688)
101. Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, et al. Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol. 1999;17(4):407-12. (Pubitemid 29343623)
102. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-7.
103. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM, Roger VL, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011;38:1601-6.
104. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum. 2008;59:1090-6.
105. Nagata-Sakurai M, Inaba M, Goto H, Kumeda Y, Furumitsu Y, Inui K, et al. Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:3061-7. (Pubitemid 37409316)
106. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360-7.
107. Nikitina NM, Rebrov AP. Cardiovascular risk in patients with rheumatoid arthritis. Terapevticheskia Arkhiv. 2009;81:29-34.
108. Novikova DS, Popkova TV, Markelova EI, Novikov AA, Mach ES. Clinical significance of the assessment of cardiac rhythm variability in patients with rheumatoid arthritis. Klin Med (Mosk). 2009;87:27-32.
109. Obradović-Tomasević B, Vujasinović-Stupar N, Tomasević R. New risk factors for cardiovascular diseases in patients with rheumatoid arthritis. Med Pregl. 2008;61(11-12):601-6.
110. Obradović-Tomasević B, Vujasinović-Stupar N, Tomasević R. The assesment of diastolic function in patients with rheumatoid arthritis. Med Pregl. 2009;62(11-12):522-8.
111. Ortega-Hernandez O-D, Pineda-Tamayo R, Pardo AL, Rojas-Villarraga A, Anaya J-M. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28:767-75.
112. Pahor A, Hojs R, Gorenjak M, Rozman B. Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int. 2006;27:119-23. (Pubitemid 46088267)
113. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J, Martin J, et al. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:964-70.
114. Panoulas VF, Douglas KMJ, Milionis HJ, Nightingale P, Kita MD, Klocke R, et al. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens. 2008;22:177-82. (Pubitemid 351266485)
115. Panoulas VF, Douglas KMJ, Smith JP, Taffé P, Stavropoulos- Kalinoglou A, Toms TE, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothel J Endothel Cell Res. 2008;15:203-12.
116. Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47:72-5. (Pubitemid 350286266)
117. Panoulas VF, Nikas SN, Smith JP, Douglas KMJ, Nightingale P, Milionis HJ, et al. Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:1550-6.
118. Panoulas VF, Milionis HJ, Douglas KMJ, Nightingale P, Kita MD, Klocke R, et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology. 2007;46:1466-70. (Pubitemid 47317096)
119. Panoulas VF, Douglas KMJ, Smith JP, Metsios GS, Elisaf MS, Nightingale P, et al., Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis. Clin Exp Hypertens. 2009;31:93-104.
120. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KMJ, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009;204:178-83.
121. Park J-H, El-Sohemy A, Cornelis MC, Kim H-A, Kim S-Y, Bae S-C. Glutathione S-transferase M1, T1, and P1 gene polymorphisms and carotid atherosclerosis in Korean patients with rheumatoid arthritis. Rheumatol Int. 2004;24:157-63. (Pubitemid 38797629)
122. Peters MJL, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JWC, Twisk JWR, et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol. 2008;35:1495-9.
123. Raterman HG, van Halm VP, Voskuyl AE, Simsek S, Dijkmans BAC, Nurmohamed MT. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. Ann Rheum Dis. 2008;67:229-32. (Pubitemid 351183313)
124. G.I. Rebrov AP, Nikitina NM, Cardiovascular risk factors in psoriatic and rheumatoid arthritis, Ter Arkh. 83 (2011) 20-24.
125. Rexhepaj N, Bajraktari G, Berisha I, Beqiri A, Shatri F, Hima F, et al. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Int J Clin Pract. 2006;60:683-8. (Pubitemid 43811648)
126. Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, Vázquez-Rodríguez TR, Miranda-Filloy JA, Fernández-Gutiérrez B, et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis. 2011;216:125-30.
127. Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study. J Rheumatol. 2011;38:236-41.
128. Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M. Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol. 1996;14:593-9.
129. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol. 2001;19:561-4. (Pubitemid 32894606)
130. Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus. 2007;16:259-64. (Pubitemid 46797889)
131. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol. 2006;33:1740-6. (Pubitemid 44373204)
132. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790-8. (Pubitemid 44955879)
133. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50:3444-9. (Pubitemid 39488668)
134. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69:1920-5.
135. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol. 2009;29:1702-8.
136. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 2006;55:531-6. (Pubitemid 44289870)
137. Tanaka K, Inaba M, Goto H, Nagata-Sakurai M, Sakai S, Yamada S, et al. Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol. 2006;33:652-8.
138. Targońska-Stepniak B, Drelich-Zbroja A, Majdan M. The relationship between carotid intima-media thickness and the activity of rheumatoid arthritis. J Clin Rheumatol. 2011;17:249-55.
139. Targońska-Stepniak B, Majdan M. Cystatin C concentration is correlated with disease activity in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40:341-6.
140. Teruel M, Martin J-E, González-Juanatey C, López-Mejias R, Miranda-Filloy JA, Blanco R, et al. Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients. Arthritis Res Ther. 2011;13:R116.
141. Toms TE, Panoulas VF, Smith JP, Douglas KMJ, Metsios GS, Stavropoulos-Kalinoglou A, et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1025-32.
142. Treharne GJ, Hale ED, Lyons AC, Booth DA, Banks MJ, Erb N, et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology. 2005;44:241-6. (Pubitemid 40277411)
143. Troelsen LN, Garred P, Jacobsen S. Mortality and predictors of mortality in rheumatoid arthritis - a role for mannose-binding lectin? J Rheumatol. 2010;37:536-43.
144. Troelsen LN, Garred P, Madsen HO, Jacobsen S. Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum. 2007;56:21-9. (Pubitemid 46106175)
145. Troelsen LN, Garred P, Christiansen B, Torp-Pedersen C, Christensen IJ, Narvestad E, et al. Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis. Mol Immunol. 2010;47:713-8.
146. Turesson C, McClelland RL, Christianson TJH, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:70-5. (Pubitemid 46049688)
147. Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne P-A, Finckh A, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2640-50.
148. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafström I, Frostegård J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol. 2010;39:447-53.
149. Wada Y, Kuroda T, Murasawa A, Tanabe N, Nakano M, Gejyo F. Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(4):482-6. (Pubitemid 41447618)
150. Walewska E, Rupińiski R, Filipowicz-Sosnowska A, Wojciechowska A. Follow-up studies of rheumatoid arthritis patients with the presence of antiphospholipid antibodies. Pol Arch Med Wewn. 2006;115:438-42. (Pubitemid 44469627)
151. Wållberg-Jonsson S, Dahlén GH, Nilsson TK, Rånby M, Rantapää-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol. 1993;12:318-24. (Pubitemid 23306865)
152. Wållberg-Jonsson S, Johansson H, Ohman ML, Rantapää- Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-71.
153. Wållberg-Jonsson S, Cederfelt M, Rantapää Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol. 2000;27:71-5. (Pubitemid 30058631)
154. Wållberg-Jonsson S, Ohman M-L, Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol. 2004;33:373-9. (Pubitemid 40006884)
155. Wang J, Hu B, Meng Y, Zhang C, Li K, Hui C. The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Clin Biochem. 2009;42:1352-7.
156. Westra J, de Groot L, Plaxton SL, Brouwer E, Posthumus MD, Kallenberg CGM, et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology. 2011;50:665-73.
157. Wisłowska M, Sypuła S, Kowalik I. Echocardiographic findings and 24 h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int. 1999;18:163-9. (Pubitemid 29294977)
158. Wisłowska M, Sypuła S, Kowalik I. Echocardiographic findings, 24 h electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol. 1998;17:369-77. (Pubitemid 28483134)
159. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36-40. (Pubitemid 36077769)
160. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 2003;48:81-9. (Pubitemid 36091651)
161. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol. 2008;14:74-7. (Pubitemid 351519191)
162. Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincón I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 2011;63:1211-20.
163. Gonzalez A, Icen M, Kremers HM, Crowson CS, Davis JM, Therneau TM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol. 2008;35:1009-14. (Pubitemid 351813145)
164. Mäki-Petäjä KM, Cheriyan J, Booth AD, Hall FC, Brown J, Wallace SML, et al. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol. 2008;129:399-405.
165. González-Juanatey C, Llorca J, González-Gay MA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther. 2011;13:R101.
166. Hinkema HJ, Nienhuis HLA, de Groot L, Smit AJ, van Roon AM, Bijl M, et al. Is small artery elasticity decreased prior to intima-media thickening in patients with longstanding rheumatoid arthritis? J Rheumatol. 2011;38:2133-40.
167. Levendoglu F, Temizhan A, Ugurlu H, Ozdemir A, Yazici M. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int. 2004;24:141-6. (Pubitemid 38797626)
168. Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez A, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo M, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35(2):112-6.
169. López A, de Guzmán J, de García Díaz D, Díez-Pérez de la Vacas MI, Cuende Quintana E, Sánchez Atrio A, Sivera Monzó I. Coronary calcification and subclinical myocardial dysfunction in rheumatoid arthritis. Revista Clínica Española. 2009;209:428-32.
170. Solomon DH. cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-7. (Pubitemid 36314415)
171. Boyer J-F, Gourraud P-A, Cantagrel A, Davignon J-L, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78:179-83.
172. Gonzalez-Gay M, Gonzalez-Juanatey C, Miranda-Filloy JA, Garcia-Porrua C, Llorca J, Martin J. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother. 2006;60:673-7.
173. Byrd VM, Zhao XM, Miller GG, Thomas JW. Detection of T cells responsive to a vascular growth factor in rheumatoid arthritis. Immunol Res. 1994;13:139-44.
174. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev. 2011;11:123-31.
175. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev. 2010;9:849-52.
176. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya J-M, Familial autoimmunity: a systematic review and meta-analysis. BMC Medicine;2013 (in press).
177. El-Gabalawy HS, Robinson DB, Smolik I, Hart D, Elias B, Wong K, et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum. 2012;64:1720-9.
178. Saevarsdottir S, Steinsson K, Grondal G, Valdimarsson H. Patients with rheumatoid arthritis have higher levels of mannan-binding lectin than their first-degree relatives and unrelated controls. J Rheumatol. 2007;34:1692-5.
179. Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol. 2007;26:759-63. (Pubitemid 46554087)
180. Reisine ST, Goodenow C, Grady KE, The impact of rheumatoid arthritis on the homemaker. Soc Sci Med. 1987/1982;25:89-95. (Pubitemid 17122275)
181. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72. (Pubitemid 14067781)
182. Cheung KP, Taylor KR, Jameson JM. Immunomodulation at epithelial sites by obesity and metabolic disease. Immunol Res. 2012;52:182-99.
183. Peters MJ, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31.
184. Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res. 2006;34:193-209. (Pubitemid 44195936)
185. del Rincón ID, Williams K, Stern MP, Freeman GL. a Escalante, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-45. (Pubitemid 34016192)
186. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev. 2011;10:582-9.
187. Liao KP. Cardiovascular disease in rheumatoid arthritis. Rheumatologist. 2012.